Ivabradine Tablet, Film Coated
Product Images NDC 51407-593

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Ivabradine (NDC 51407-593). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-592-60ol .jpg (51407 592 60ol)

This is a pharmaceutical product labeled with the NDC code 51407-592-60. It contains film-coated tablets with 5 mg of ivabradine hydrochloride. The pharmacist is advised to dispense the medication guide to each patient. The dosage information is available in the prescribing information. The package is child-resistant and should be stored at 25°C with excursions permitted between 15° - 30°C. The product is marketed by GSMS, Incorporated in Camarillo, CA, USA.*

FDA Label Image

51407-593-60ol.jpg (51407 593 60ol)

This text is a description of Ivabradine tablets for oral use. It includes important information such as dosage instructions, storage conditions, manufacturer details, and a reminder to keep the medication out of children's reach. The package is child-resistant and contains 60 film-coated tablets, each containing 7.5 mg of ivabradine. The medication guide is supposed to be dispensed to each patient. For more information, individuals can consult the prescribing information accompanying the tablets.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 01)

Not available.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 02)

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 03)

This is a data table showing the proportion of subjects with heart failure hospitalization or cardiovascular death over time, indicated in months, based on the number of subjects at risk under the placebo and Coranor treatment. Placebo group has 3264 subjects at the start, with decreasing numbers over months. Coranor group starts with 3241 subjects. The data displayed can be utilized for analyzing and comparing the efficacy of the treatments in preventing heart failure hospitalizations and cardiovascular deaths.*

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 04)

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 05)

FDA Label Image

Image (9afa6c68 F4c3 4d3b 92d7 765f19e0ba22 92 2)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.